Perspective: What next for treatment?
Memorial Sloan Kettering Cancer Center in New York City.
Robert J
RJ
Motzer
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000188:drug therapy / Q000235:genetics / Q000276:immunology; D018450:Disease Progression; D055088:Early Detection of Cancer; D006040:Goals; D006801:Humans; D007167:Immunotherapy; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000235:genetics; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics
D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; D051794:Von Hippel-Lindau Tumor Suppressor Protein; C497446:VHL protein, human